Enhanced noradrenergic neuronal activity increases homovanillic acid levels in cerebrospinal fluid.
Idazoxan, a highly specific and selective alpha 2-adrenoceptor antagonist, caused a dose-dependent increase in the concentration of homovanillic acid (HVA) a metabolite of 3,4-dihydroxyphenylethylamine, in cisternal CSF of freely moving rats. This increase in HVA level could be antagonized by the alpha 2-adrenoceptor agonist medetomidine. The increase was directly proportional to the concurrent elevation in level of 3-methoxy-4-hydroxyphenylglycol, a metabolite of noradrenaline, in the CSF of individual rats and followed a similar time course. It is suggested that the HVA level in CSF may be increased under conditions of enhanced noradrenergic activity and that, in such situations, it reflects noradrenergic rather than dopaminergic neuronal activity. Care should be taken, therefore, when changes in central dopaminergic activity are assessed by measurements of HVA level in CSF.
D000818:Animals; D004146:Dioxanes / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D019329:Idazoxan; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D020926:Medetomidine; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D009474:Neurons / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology
D004146:Dioxanes; D007093:Imidazoles; D011942:Receptors, Adrenergic, alpha; D008734:Methoxyhydroxyphenylglycol; D020926:Medetomidine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid; D019329:Idazoxan